Latest Research Highlights
CAR T-Cell Therapy and the Cytokine Storm: The Balancing Act at the Center of Next-Generation Cancer Therapies
Recent advances in chimeric antigen receptor (CAR) T-cell therapy have opened exciting new avenues for the treatment of a variety of malignancies. Cytokine release syndrome (CRS), a powerful immune response to activated CAR T cells, is the primary side effect of CAR T-cell therapy, but existing CRS treatments can make CAR T-cell treatment less effective. In two recent studies, researchers used multiplexed cytokine immunoassays to better understand how CAR T-cell therapy triggers CRS and to identify strategies for early intervention in CRS development.
Efficacy of a Novel Treatment for Multiple Myeloma Established by Flow Cytometry
Autologous stem cell transplantation (ASCT) is an effective treatment strategy for multiple myeloma (MM) but isolating enough hematopoietic stem and progenitor cells (HSPCs) for transplantation can be challenging. The selective CXCR4 inhibitor motixafortide has been shown to be a safe and efficacious HSPC mobilization agent in a phase 2 trial when paired with G-CSF. Crees et al. (2023) report the results of the phase 3 trial, in which they used the ZE5 Cell Analyzer to explore motixafortide’s mobilizing effects.
